scholarly article | Q13442814 |
P50 | author | David J. Bond | Q52146724 |
Mauricio Kunz | Q56935942 | ||
Beny Lafer | Q42305969 | ||
Roumen Milev | Q42317690 | ||
Raymond W. Lam | Q42883552 | ||
P2093 | author name string | F Kapczinski | |
J Quevedo | |||
V Sharma | |||
H Qian | |||
H Wong | |||
L N Yatham | |||
L T Young | |||
A Schaffer | |||
M Kauer-Sant'Anna | |||
S V Parikh | |||
S Beaulieu | |||
R Dias | |||
A da Cunha | |||
P Baruch | |||
P H Silverstone | |||
N Walji | |||
A Daigneault | |||
P2860 | cites work | Manual for the Extrapyramidal Symptom Rating Scale (ESRS). | Q50279993 |
Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. | Q52900826 | ||
Obesity in Patients With Bipolar Disorder | Q57452985 | ||
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients | Q69903875 | ||
A rating scale for depression | Q24564540 | ||
Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder | Q28250466 | ||
A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
A rating scale for mania: reliability, validity and sensitivity | Q29619299 | ||
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. | Q34486939 | ||
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 | ||
Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model | Q36539425 | ||
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 | ||
Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial | Q38376022 | ||
Antipsychotic agents and bipolar disorder. | Q41692615 | ||
Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder | Q43130555 | ||
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 | ||
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone | Q44824135 | ||
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). | Q46086886 | ||
The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 | ||
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). | Q46519540 | ||
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 | ||
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study | Q48310435 | ||
A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder | Q48697520 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | risperidone | Q412443 |
manic episode | Q18966903 | ||
P304 | page(s) | 1050-1056 | |
P577 | publication date | 2015-10-13 | |
P1433 | published in | Molecular Psychiatry | Q6895973 |
P1476 | title | Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial | |
P478 | volume | 21 |
Q39116844 | Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study |
Q37197203 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods |
Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
Q89665749 | Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better |
Q53742036 | Defining the role of SGAs in the long-term treatment of bipolar disorder. |
Q89665776 | Evidence-Based Principles for Bipolar Disorder Treatment |
Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
Q52661474 | Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. |
Q47863136 | Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression |
Q47553353 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. |
Q94569502 | Stabilization Beyond Mood: Stabilizing Patients With Bipolar Disorder in the Various Phases of Life |
Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
Search more.